Palvella Therapeutics (PVLA) to Release Quarterly Earnings on Monday

Palvella Therapeutics (NASDAQ:PVLA) is anticipated to release its earnings data before the market opens on Monday, March 31st. Analysts expect Palvella Therapeutics to post earnings of ($0.39) per share for the quarter.

Palvella Therapeutics Stock Up 0.9 %

Shares of NASDAQ:PVLA traded up $0.26 on Monday, reaching $28.40. 23,005 shares of the company’s stock were exchanged, compared to its average volume of 61,238. The company’s fifty day moving average price is $18.78. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $29.27. The firm has a market cap of $318.68 million, a P/E ratio of -2.35 and a beta of 0.54.

Analyst Ratings Changes

A number of brokerages have issued reports on PVLA. Scotiabank began coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $38.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $39.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Finally, TD Cowen initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 price target on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $42.75.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.